Get started
Abivax SAAA

Abivax SA

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

ABVX chart


Full chart

ABVX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪433.64 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.02 USD
Net income (FY)
‪−190.64 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪55.16 M‬
Beta (1Y)
1.22

About ABIVAX


Sector
Health Technology
Industry
Pharmaceuticals: Other
CEO
Marc M. P. de Garidel
Website
abivax.com
Headquarters
Paris
Founded
2013
FIGI
BBG01JLQNZ03
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ABVX news



No news here

Looks like there's nothing to report right now

Reload

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.